.png)
Large Pharmaceutical
HTA, Value & Evidence, Global Access Strategy & Pricing
Phase III
Dermatology
Subscribe to our newsletter to receive the latest case studies.
Large Pharmaceutical
HTA, Value & Evidence, Global Access Strategy & Pricing
Phase III
Dermatology
The client was preparing to bring a systemic therapy for a dermatologic condition into HTA-driven markets.
While clinical data supported approval, reimbursement decisions would depend on how disease burden, long-term value, and uncertainty were interpreted by HTA bodies.
Early signals from affiliates suggested misalignment across markets; differences in burden framing, economic assumptions, and anticipated objections that could surface late and slow access.
The client engaged Alkemi to identify likely HTA challenges early and bring markets into alignment before launch.
1. Established a core working team across Value & Evidence and Market Access to align on objectives and success criteria.
2. Conducted structured interviews with country affiliates to understand local reimbursement pathways, current treatment costs, and anticipated HTA challenges.
3. Designed and led a full-day hybrid strategy workshop focused on identifying access risks and evaluating mitigation options across markets.
4. Synthesized insights into clear strategic outputs and country-level tools to support ongoing HTA planning and execution.
Identify where access risk would emerge and address it early.
"Thanks for sharing the final materials! Many thanks to you and the rest of the Alkemi team for a success project. We really appreciated the excellent collaboration and quality work. It’s been a pleasure working with all of you on this project! Looking forward to the next one…" - Senior Director, Global HTA, Value & Evidence Strategy
Affiliates gained clarity on anticipated HTA challenges and how global strategy supported local access planning.
The team prioritized evidence, modeling refinements, and communication support tied to reimbursement risk.
Early alignment across markets lowered the likelihood of late-stage access delays and improved confidence in pricing and access discussions.